Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748)
Source: Aarti Pharmalabs Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Aarti Pharmalabs Limited operates an integrated pharmaceutical manufacturing model centered on high-barrier chemistry, backward integration, and long-term customer partnerships across 50+ countries. The business model spans three complementary revenue drivers: Xanthine Derivatives and Allied Products, Generic APIs & Intermediates, and Contract Development and Manufacturing Organisation (CDMO/CMO) services.
- Xanthine Derivatives Portfolio: Caffeine Anhydrous (largest producer in India), Theophylline Anhydrous, Aminophylline, Etofylline, and allied bio-catalytic and bio-synthetic Xanthine compounds. Serves beverage giants and pharmaceutical formulation players across global markets.
- Generic APIs & High-Potency APIs (HPAPIs): Commercialized portfolio of 61 generic APIs catering to critical therapeutic categories including Oncology/Cytotoxic agents, Corticosteroids, Cardiovascular, Anti-Diabetic, Anti-Asthmatic, Central Nervous System (CNS), Calcimimetic, Decongestant, Skin Care, and Analgesic applications.
- Pharmaceutical Intermediates: Over 140 commercialised generic and custom intermediates supported by 44 Certificate of Suitability (CEP) approvals from European regulatory bodies.
- CDMO Services & Project Pipeline: Integrated custom development services covering synthetic route scouting, Design of Experiments (DoE), Quality by Design (QbD) studies, process safety validation, analytical method development, CMC documentation, and scale-up execution. Active project portfolio comprises 54 projects (35 commercial-stage programmes and 19 under development at customer ends) across 21 innovator clients.
📋 Quick Facts / Company Snapshot: Aarti Pharmalabs Limited (NSE: AARTIPHARM | BSE: 543748)
Aarti Pharmalabs Limited (“APL” or “the Company”) is a globally recognised, integrated pharmaceutical manufacturer offering generic Active Pharmaceutical Ingredients (APIs), advanced pharmaceutical intermediates, Contract Development and Manufacturing Organisation (CDMO/CMO) services, and Xanthine derivatives. Demerged from Aarti Industries Limited in 2022, the Company combines process chemistry, scale-up engineering, and backward-integrated manufacturing infrastructure across Maharashtra and Gujarat.
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Aarti Pharmalabs Limited |
| Corporate Identity Number (CIN) | L24100GJ2019PLC110964 |
| ISIN | INE0LRU01027 |
| Stock Exchange Listing | BSE: 543748 | NSE: AARTIPHARM |
| Date of Incorporation / Founding Year | Incorporated November 22, 2019 (Pharma roots established in 1984 within Aarti Industries Limited; demerged in 2022) |
| Founders / Key Founding Figures | Shri Chandrakant V. Gogri (Founder & Chairman Emeritus) |
| Registered Office | Plot No. 22/C/1 & 22/C/2, 1st Phase, GIDC Vapi – 396195, District Valsad, Gujarat, India |
| Corporate Office | Embassy Park 247, Tower C, 401, 4th Floor, LBS Marg, Vikhroli (W), Mumbai – 400083, Maharashtra, India |
| Telephone & Official IR Email | Tel: +91 022-69436100 / +91 22 6797 6697 | Email: investorrelations@aartipharmalabs.com / info@aartipharmalabs.com |
| Chairman & Managing Leadership | Shri Rashesh C. Gogri (Chairman, Non-Executive Director; re-designated Managing Director w.e.f. October 01, 2026) | Smt. Hetal Gogri Gala (Vice Chairperson and Managing Director; re-designated Whole-time Director w.e.f. October 01, 2026) | Shri Narendra J. Salvi (Managing Director) |
| Key Managerial Personnel (KMP) | Shri Piyush P. Lakhani (Chief Financial Officer) | Shri Jeevan B. Mondkar (Company Secretary, Legal Head & Compliance Officer) |
| Promoter Group & Holding | Aarti Group (Promoter & Promoter Group Shareholding: 43.08%) |
| Industry / Sector Classification | Pharmaceuticals, Generic APIs, Intermediates, CDMO & Xanthine Derivatives (NIC Codes: 210, 1104) |
| Workforce & Human Capital | Total Workforce: 4,218 personnel (Permanent Employees: 1,899; Other than Permanent Employees: 134; Permanent Workers: 522; Contractual/Other Workers: 1,663; Overall Employee Turnover Rate: 23.45%) |
| Manufacturing Plants & Infrastructure Footprint | 15 Operating Units/Facilities (including 3 R&D Centres across Dombivli, Nerul, and Vapi) concentrated in Maharashtra and Gujarat |
| Credit Ratings | CRISIL Ratings Limited: CRISIL AA-/Stable (Long-Term Issuer Rating & Bank Loan Facilities) |
| Statutory & Secretarial Auditors | Statutory Auditors: M/s Gokhale & Sathe, Chartered Accountants | Secretarial Auditors: M/s Mehta & Mehta, Company Secretaries | Cost Auditors: Smt. Ketki D. Visariya & Co., Cost Accountants |
| Registrar & Share Transfer Agent (RTA) | MUFG Intime India Private Limited (formerly Link Intime India Private Limited), C 101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400083 |
🏢 The Corporate Identity: Aarti Pharmalabs Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Aarti Pharmalabs Limited operates an integrated pharmaceutical manufacturing model centered on high-barrier chemistry, backward integration, and long-term customer partnerships across 50+ countries. The business model spans three complementary revenue drivers: Xanthine Derivatives and Allied Products, Generic APIs & Intermediates, and Contract Development and Manufacturing Organisation (CDMO/CMO) services.
By leveraging deep synthetic organic chemistry, scale-up engineering, continuous flow reaction capability, and dedicated process safety infrastructure, APL moves small molecules seamlessly from early-stage route design to multi-ton commercial production. The Company’s strategic moat rests on complete backward integration for major APIs and Xanthine derivatives, eliminating dependence on Chinese raw materials and offering supply security to global pharmaceutical, beverage, and nutraceutical clients.
- Xanthine Derivatives Leadership: India’s largest manufacturer of Xanthine derivatives (caffeine, theophylline, aminophylline, etofylline) with an operating capacity of 6,000 MTPA expanding to 9,000 MTPA, holding a 15–20% global market share.
- Regulatory-Compliant API Engine: Broad generic API and intermediate portfolio backed by USFDA, EU GMP, EDQM, KFDA, ANVISA, and COFEPRIS accredited facilities, holding 60 US DMFs and 44 CEP approvals.
- Rapidly Scaling CDMO Platform: End-to-end innovator support from route scouting to commercial drug substance manufacturing, generating CDMO revenue of ₹276.00 Crores in FY 2025-26 across 54 active projects.
- Strategic Port-Proximate Base: Deliberately concentrated operations across Maharashtra and Gujarat, facilitating supply chain efficiency and shared engineering oversight.
The Founders, Promoters & Their Legacy
The origin of Aarti Pharmalabs traces back to the founding legacy of Shri Chandrakant V. Gogri, Founder and Chairman Emeritus of the Aarti Group. A Chemical Engineering graduate from the Institute of Chemical Technology (formerly UDCT), Shri Gogri spearheaded the expansion of Aarti Group into one of India’s specialty chemical and pharmaceutical conglomerates. His contributions to the chemical industry earned him the Lala Shriram National Award for Leadership in the Chemical Industry (2015) and the ICC D.M. Trivedi Lifetime Achievement Award (2019).
The leadership of APL is guided by Chairman Shri Rashesh C. Gogri, Vice Chairperson & Managing Director Smt. Hetal Gogri Gala, and Managing Director Shri Narendra J. Salvi. Shri Rashesh C. Gogri holds a degree in Production Engineering from Mumbai University and brings over 29 years of chemical and pharmaceutical operational experience. Smt. Hetal Gogri Gala, an Electronics Engineer with executive management education from IIM Ahmedabad, oversees global supply chain, procurement, and human resources, bringing over 23 years of industry experience. Shri Narendra J. Salvi manages execution, site operations, and compliance.
The Journey: Corporate History & Key Milestones
The pharmaceutical capabilities of APL were cultivated over four decades within Aarti Industries Limited before emerging as a standalone publicly listed entity.
- 1984–2005 (Formative Years): Commenced first API manufacturing unit in Dombivli (Unit 1), launched the Xanthine business, incorporated Aarti Organic Private Limited, and commissioned Tarapur Unit 4 for generic APIs.
- 2008–2019 (Build-Up & Global Accreditations): Completed USFDA and EU GMP audits at Tarapur Unit 4; secured EDQM certification for Bicalutamide; commissioned Unit 5 caffeine plant at Vapi with 100 MT monthly capacity; completed COFEPRIS Mexico audits.
- 2022 (Demerger & Independence): Demerged the pharmaceutical business of Aarti Industries Limited into Aarti Pharmalabs Limited; acquired 80 acres of land at Atali, Gujarat; operationalised Block V at Tarapur Unit 4; enhanced Xanthine capacity to 5,000 MTPA.
- 2023–2025 (Platform Scale & ESG Leadership): Commissioned the 21 MWp captive solar power project at Akola, Maharashtra; operationalised the third R&D centre; achieved EcoVadis Gold rating (top 5% globally); secured Science Based Targets initiative (SBTi) validation for net-zero carbon pathways.
- 2025–2026 (Atali Operationalisation & Xanthine Expansion): Commissioned Phase 1 of the greenfield Atali facility (450+ KL reactor capacity); executed brownfield Xanthine expansion at Tarapur Unit 5 targeting 9,000 MTPA total capacity by June 2026.
The Corporate Umbrella & Group Structure
Aarti Pharmalabs Limited functions as the ultimate holding operating company for its pharmaceutical operations, supported by two wholly-owned direct subsidiaries and one joint venture entity.
- Aarti Pharmachem Limited: Wholly-owned domestic subsidiary incorporated in India to support specialized chemical and pharmaceutical intermediate manufacturing.
- Aarti USA Inc.: Wholly-owned international subsidiary incorporated in the United States, facilitating sales, business development, regulatory liaison, and customer relations across North America.
- Ganesh Polychem Limited: Joint venture entity (50% equity stake held by APL, transitioned from a joint operation to an equity-accounted joint venture effective April 01, 2025), manufacturing specialized chemical intermediates.
⚙️ The Business Engine: Aarti Pharmalabs Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
APL organizes its operational reporting around three core divisions derived from deep synthetic chemistry platforms. During FY 2025-26, the Company generated consolidated operational revenue of ₹1,819.44 Crores.
| Business Segment | FY 2025-26 Revenue (₹ in Crores) | % Share of Operational Mix | Installed Capacity / Scale Indicators | Primary End-Use Markets & Applications |
|---|---|---|---|---|
| Xanthine Derivatives & Allied Products | 792.00 | 47.50% | 6,000 MTPA (Expanding to 9,000 MTPA) | Cola beverages, energy drinks, pharmaceuticals, and nutraceutical supplements |
| API and Intermediates | 600.00 | 36.00% | 1,500+ KL Multipurpose Reactor Capacity, 14 API Finished Lines | Regulated & emerging market generic drugs (Oncology, Cardiovascular, Anti-Asthmatic) |
| CDMO and CMO Services | 276.00 | 16.50% | 3 Dedicated R&D Centres, Pilot Plants, 450+ KL Atali Block 1 | Innovator NCE development, clinical-stage trial batches, commercial drug substance supply |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
APL’s product spectrum covers small-molecule generic APIs, advanced Key Starting Materials (KSMs), Regulatory Starting Materials (RSMs), building blocks, Xanthines, and custom-synthesised active ingredients.
- Xanthine Derivatives Portfolio: Caffeine Anhydrous (largest producer in India), Theophylline Anhydrous, Aminophylline, Etofylline, and allied bio-catalytic and bio-synthetic Xanthine compounds. Serves beverage giants and pharmaceutical formulation players across global markets.
- Generic APIs & High-Potency APIs (HPAPIs): Commercialized portfolio of 61 generic APIs catering to critical therapeutic categories including Oncology/Cytotoxic agents, Corticosteroids, Cardiovascular, Anti-Diabetic, Anti-Asthmatic, Central Nervous System (CNS), Calcimimetic, Decongestant, Skin Care, and Analgesic applications.
- Pharmaceutical Intermediates: Over 140 commercialised generic and custom intermediates supported by 44 Certificate of Suitability (CEP) approvals from European regulatory bodies.
- CDMO Services & Project Pipeline: Integrated custom development services covering synthetic route scouting, Design of Experiments (DoE), Quality by Design (QbD) studies, process safety validation, analytical method development, CMC documentation, and scale-up execution. Active project portfolio comprises 54 projects (35 commercial-stage programmes and 19 under development at customer ends) across 21 innovator clients.
- Customer Concentration & Raw Material Sourcing: In compliance with Ind AS 115 disclosures, no single external customer contributed 10% or more to APL’s total consolidated revenue during FY 2025-26, highlighting a diversified global client base. Raw material procurement relies on a pass-through pricing mechanism (RM-plus pricing) for Xanthine and CDMO contracts, mitigating cost volatility in key solvents and petro-chemical feedstocks.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Caffeine Anhydrous (IP/BP/USP/EP) | Xanthine Derivatives & Allied Products | Global food, cola beverage, energy drink, and pharmaceutical formulation manufacturers; non-Chinese fully backward-integrated supply security |
| Theophylline & Aminophylline | Xanthine Derivatives & Allied Products | Global respiratory healthcare markets; anti-asthmatic and bronchodilator formulations |
| Bicalutamide API | API and Intermediates (Oncology) | USFDA and EU GMP accredited anti-cancer API supplied to regulated generic formulation manufacturers |
| Cytotoxic & Corticosteroid APIs | API and Intermediates (HPAPI) | High-potency active pharmaceutical ingredients manufactured in dedicated containment suites for global oncology markets |
| Custom NCE Intermediates & RSMs | CDMO and CMO Services | Global innovator pharmaceutical and biotechnology firms across Phase I–III clinical development and commercial launch |
Mapping the Domestic & Global Reach (India vs. Exports)
APL serves customers across more than 50 countries, with international sales contributing 55.95% of total operational revenues in FY 2025-26.
| Geographic Region | FY 2025-26 Revenue (₹ in Crores) | % Share of Total Revenue | Market Characteristics & Growth Focus |
|---|---|---|---|
| International (Exports) | 1,018.00 | 55.95% | Regulated markets (US, EU, Japan) and Rest of World (ROW); focus on USFDA-approved generic APIs, CEP-backed intermediates, and CDMO partnerships |
| Domestic (India) | 801.44 | 44.05% | Beverage giants, domestic generic formulation leaders, and local pharmaceutical manufacturers; includes export benefits/incentives of ₹26.95 Crores |
| Total Operational Revenue | 1,819.44 | 100.00% | Comprehensive global footprint across 50+ export destinations |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The Company operates 15 units across Maharashtra and Gujarat, structured to provide seamless scale-up from milligram laboratory synthesis to multi-ton plant production.
- Dombivli Cluster (Maharashtra): Unit 1 (API, Intermediates, CDMO; USFDA accredited) and Unit 2 (Custom Synthesis Division, API, CDMO; USFDA accredited).
- Tarapur Cluster (Maharashtra): Unit 3 (Xanthine derivatives; cGMP), Unit 4 (API, CDMO-API; USFDA, EU GMP, EDQM, KFDA, COFEPRIS, ANVISA accredited), Unit 5 (Xanthine Caffeine plant; cGMP, FSSC 22000, Halal, Kosher), Unit 6 (Intermediates, Xanthine, Specialty products), Unit 7, Unit 8, and Unit 9.
- Vapi & Atali Base (Gujarat): Custom Synthesis Division at Vapi (API, Intermediates, CDMO; USFDA accredited); Greenfield platform at Atali, Bharuch (80-acre site; Phase 1 commissioned with 450+ KL reactor capacity for CDMO and advanced intermediates).
- R&D Infrastructure: 3 dedicated state-of-the-art R&D centres located at Nerul and Dombivli in Maharashtra, and Vapi in Gujarat. Supported by 122 process scientists, 21 PhDs, specialized flow chemistry loops, continuous bio-catalysis reaction blocks, and process safety laboratories (equipped with Thermal Screening Units and Reaction Calorimeters).
📊 The Financial Health: Aarti Pharmalabs Financial Statements & Numbers Simplified
Multi-Year Financial Highlights
Consolidated multi-year performance highlights for APL reflect significant capital expenditure execution, strong CDMO revenue momentum, and temporary margin pressures driven by raw material inflation and product mix adjustments.
| Financial Metric (₹ in Crores) | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Revenue from Operations | 1,819.44 | 2,115.07 | 1,852.60 | -13.98% |
| EBITDA | 402.42 | 464.37 | 386.00 | -13.34% |
| EBITDA Margin (%) | 22.12% | 21.96% | 20.84% | – |
| Profit After Tax (PAT) | 174.71 | 272.40 | 216.90 | -35.86% |
| PAT Margin (%) | 9.60% | 12.88% | 11.71% | – |
| Basic Earnings Per Share (₹) | 19.27 | 30.06 | 23.93 | -35.89% |
| Total Equity (Net Worth) | 2,124.60 | 1,989.91 | 1,711.73 | +6.77% |
| Net Debt-to-Equity (x) | 0.32x | 0.19x | 0.14x | +68.42% |
| Return on Equity (ROE %) | 8.22% | 13.69% | 12.30% | – |
| Return on Capital Employed (ROCE %) | 8.95% | 16.04% | 15.70% | – |
| Capital Outlay / CapEx Execution | 409.37 | 402.04 | 146.00 | +1.82% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
The consolidated financial statement for FY 2025-26 incorporates Ganesh Polychem Limited as an equity-accounted joint venture (effective April 01, 2025), impacting direct year-on-year line-item comparability.
| Consolidated Statement of Profit & Loss Item | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 1,819.44 | 2,115.07 | -13.98% |
| Other Income | 9.75 | 8.43 | +15.66% |
| TOTAL INCOME | 1,829.19 | 2,123.50 | -13.86% |
| Cost of Materials Consumed | 830.06 | 835.80 | -0.69% |
| Purchase of Stock-in-Trade | 55.95 | 176.63 | -68.32% |
| Changes in Inventories of Finished Goods, Stock-in-Trade & WIP | (51.18) | 64.22 | N/M |
| Employee Benefits Expense | 173.09 | 161.96 | +6.87% |
| Finance Costs | 46.90 | 26.90 | +74.35% |
| Depreciation & Amortisation Expenses | 104.34 | 86.90 | +20.07% |
| Foreign Exchange Loss / (Gain) | 33.21 | (1.69) | N/M |
| Other Expenses | 409.10 | 412.09 | -0.73% |
| TOTAL EXPENSES | 1,601.47 | 1,762.81 | -9.15% |
| Profit from Operations before Joint Venture, Exceptional Items & Tax | 227.72 | 360.69 | -36.87% |
| Share of Profit of Joint Ventures | 8.00 | 0.00 | N/M |
| Exceptional Items Loss | (2.79) | 0.00 | N/M |
| Profit Before Tax (PBT) | 232.92 | 360.69 | -35.42% |
| Tax Expenses (Current Tax, Earlier Year Tax & Deferred Tax) | 58.21 | 88.28 | -34.06% |
| Profit for the Year (PAT) | 174.71 | 272.40 | -35.86% |
| Other Comprehensive Income / (Loss) (Net of Tax) | (6.24) | (9.76) | -36.07% |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 168.47 | 262.65 | -35.86% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
APL’s balance sheet reflects substantial non-current asset creation, with total assets expanding to ₹3,481.71 Crores as of March 31, 2026, driven by ongoing capital investment at Atali and Tarapur.
| Consolidated Balance Sheet Item | As at March 31, 2026 (₹ in Crores) | As at March 31, 2025 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| 1. Non-Current Assets | |||
| Property, Plant and Equipment | 1,335.92 | 1,088.69 | +22.71% |
| Capital Work-in-Progress (CWIP) | 305.21 | 306.58 | -0.45% |
| Right of Use Assets | 65.53 | 15.43 | +324.69% |
| Goodwill | 0.00 | 1.78 | -100.00% |
| Other Intangible Assets | 36.01 | 30.67 | +17.41% |
| Intangible Assets Under Development | 87.87 | 67.77 | +29.66% |
| Non-Current Financial Assets – Investments | 193.85 | 29.24 | +562.96% |
| Non-Current Financial Assets – Loans & Other Financial Assets | 43.21 | 21.33 | +102.58% |
| Other Non-Current Assets | 16.81 | 22.75 | -26.11% |
| Total Non-Current Assets | 2,084.41 | 1,584.24 | +31.57% |
| 2. Current Assets | |||
| Inventories | 640.31 | 587.58 | +8.97% |
| Current Financial Assets – Investments | 0.00 | 47.56 | -100.00% |
| Current Financial Assets – Trade Receivables | 583.32 | 575.40 | +1.38% |
| Current Financial Assets – Cash and Cash Equivalents | 8.53 | 6.73 | +26.75% |
| Current Financial Assets – Bank Balances & Loans | 1.59 | 4.09 | -61.12% |
| Current Tax Assets & Other Current Assets | 163.54 | 96.82 | +68.91% |
| Total Current Assets | 1,397.29 | 1,318.19 | +6.00% |
| TOTAL ASSETS | 3,481.71 | 2,902.43 | +19.96% |
| EQUITY AND LIABILITIES | |||
| 1. Equity | |||
| Equity Share Capital | 45.33 | 45.32 | +0.02% |
| Other Equity | 2,079.28 | 1,944.59 | +6.93% |
| Total Equity (Net Worth) | 2,124.60 | 1,989.91 | +6.77% |
| 2. Non-Current Liabilities | |||
| Non-Current Borrowings | 185.81 | 103.56 | +79.42% |
| Lease Liabilities (Non-Current) | 52.18 | 11.67 | +347.13% |
| Deferred Tax Liabilities (Net), Provisions & Financial Liabilities | 181.54 | 144.22 | +25.88% |
| Total Non-Current Liabilities | 419.53 | 259.45 | +61.70% |
| 3. Current Liabilities | |||
| Current Borrowings | 499.82 | 292.80 | +70.70% |
| Lease Liabilities (Current) | 16.55 | 5.09 | +225.15% |
| Trade Payables (MSME & Others) | 334.54 | 277.83 | +20.41% |
| Other Current Financial Liabilities, Provisions & Tax Liabilities | 86.66 | 77.35 | +12.04% |
| Total Current Liabilities | 937.57 | 653.07 | +43.56% |
| Total Liabilities (Excluding Equity) | 1,357.10 | 912.52 | +48.72% |
| TOTAL EQUITY AND LIABILITIES | 3,481.71 | 2,902.43 | +19.96% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
In accordance with Schedule III requirements, APL provides detailed explanations for key financial ratio variances exceeding 25% year-on-year.
| Statutory Ratio | FY 2025-26 | FY 2024-25 | YoY Change (%) | Management Explanation for Variance >25% |
|---|---|---|---|---|
| Current Ratio (x) | 1.59 | 2.03 | -21.78% | Within normal operating bounds; driven by short-term working capital drawdowns for project execution. |
| Net Debt-to-Equity (x) | 0.35 | 0.18 | +95.44% | Increase in total debt attributable to term loans drawn to finance capital expenditure at Atali and Tarapur. |
| Debt Service Coverage Ratio (DSCR x) | 6.95 | 14.36 | -51.60% | Reduction driven by higher finance costs associated with new debt drawdowns and lower net profit. |
| Net Profit Margin (%) | 174.71 | 12.88% | -25.44% | Profitability impacted by elevated operating costs of newly commissioned facilities, pricing pressure in generic APIs, and foreign exchange mark-to-market movements. |
| Return on Equity (ROE %) | 8.49% | 14.54% | -41.59% | Moderation in net profit relative to expanded equity base following ongoing capital investment. |
| Return on Capital Employed (ROCE %) | 11.46% | 18.74% | -38.85% | Lower EBIT due to higher depreciation, finance costs, and un-utilised capacity during trial runs of new blocks. |
| Return on Investment (ROI %) | 9.78% | 15.59% | -37.26% | Contrasted against expanding asset base prior to full commercial ramp-up of Atali Phase 1. |
| Inventory Turnover Ratio (x) | 1.36 | 1.75 | -22.30% | Higher raw material inventory held to ensure supply chain resilience during plant commissioning. |
Cash Flow: Tracking the Money Movement
Operating cash flows remained healthy at ₹261.93 Crores, supporting an aggressive internal capital expenditure programme of ₹409.37 Crores during FY 2025-26.
| Consolidated Cash Flow Statement Indicator | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Net Cash Flow from Operating Activities | 261.93 | 330.14 | -20.66% |
| Purchase of Property, Plant and Equipment (CapEx / CWIP) | 409.37 | 402.04 | +1.82% |
| Intangible Asset Additions & Development | (38.95) | (41.84) | -6.91% |
| Other Investing Cash Flow (Proceeds from Investments, Interest) | 17.60 | 31.41 | -43.97% |
| Net Cash Flow Used in Investing Activities | (430.72) | (412.48) | +4.42% |
| Proceeds from Long-Term & Working Capital Borrowings (Net) | 264.25 | 127.86 | +106.67% |
| Finance Cost & Lease Liabilities Paid | (57.41) | (30.71) | +86.94% |
| Dividends Paid to Equity Shareholders | (36.26) | (31.72) | +14.31% |
| Net Cash Flow from Financing Activities | 170.58 | 65.43 | +160.71% |
| Net Increase / (Decrease) in Cash & Cash Equivalents | 1.80 | (16.90) | N/M |
| Cash & Cash Equivalents at Beginning of Year | 6.73 | 23.63 | -71.52% |
| Cash & Cash Equivalents at End of Year | 8.53 | 6.73 | +26.75% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
APL executed a consolidated capital outlay of ₹409.37 Crores during FY 2025-26, focusing on two strategic expansion projects.
- Atali Greenfield Project (Bharuch, Gujarat): ₹400 Crores estimated project investment on an 80-acre land parcel. Block 1 (~450 KL capacity) achieved 80% operational readiness by Q4 FY 2025-26, providing dedicated intermediate and CDMO capacity with 8–10x expansion headroom.
- Tarapur Brownfield Expansion (Unit 5, Maharashtra): ₹210 Crores investment expanding total Xanthine derivative capacity from 5,000 MTPA to 9,000 MTPA. Inaugurated in June 2026, the facility supports wallet-share expansion among beverage and pharmaceutical clients.
- R&D Spending Intensity: Consolidated R&D expenditure reached ₹49.54 Crores (Standalone R&D outlay ₹65.00 Crores, representing 7.4% of API, Intermediates, and CDMO sales).
- Foreign Exchange Earnings & Outgo: Section 134(3)(m) disclosures reflect Total Foreign Exchange Earned of ₹1,005.56 Crores against Total Foreign Exchange Outgo of ₹310.99 Crores, yielding Net Foreign Exchange Earnings of ₹694.57 Crores.
👥 Power & Control: Aarti Pharmalabs Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
APL’s Board of Directors comprises 12 members, maintaining a balanced mix of executive leadership, promoter expertise, and 50% Independent Directors (including two women Independent Directors).
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Shri Rashesh C. Gogri | Chairman (re-designated Managing Director w.e.f. October 01, 2026) | 00066291 | Non-Executive / Promoter |
| Smt. Hetal Gogri Gala | Vice Chairperson & Managing Director (re-designated Whole-time Director w.e.f. October 01, 2026) | 00005499 | Executive / Promoter |
| Shri Narendra J. Salvi | Managing Director | 00299202 | Executive |
| Shri Rajendra V. Gogri | Non-Executive Director (retiring by rotation at 7th AGM, not seeking re-appointment) | 00061003 | Non-Executive / Promoter |
| Shri Parimal H. Desai | Non-Executive Director | 00009272 | Non-Executive |
| Smt. Nehal Garewal | Non-Executive Director | 01750146 | Non-Executive / Promoter Group |
| Shri Bhavesh R. Vora | Independent Director (Audit Committee Chairperson) | 00267604 | Independent |
| Dr. Vinay G. Nayak | Independent Director | 02577389 | Independent |
| Prof. Vilas G. Gaikar | Independent Director | 00033383 | Independent |
| Smt. Rupal A. Vora | Independent Director | 07096253 | Independent |
| Smt. Jeenal K. Savla | Independent Director (Nomination & Remuneration Committee Chairperson) | 07545244 | Independent |
| Shri Pradeep H. Thakur | Independent Director | 00685992 | Independent |
| Shri Piyush P. Lakhani | Chief Financial Officer (CFO) | – | Key Managerial Personnel |
| Shri Jeevan B. Mondkar | Company Secretary & Compliance Officer / Legal Head | – | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
As of March 31, 2026, the paid-up share capital of APL stood at ₹45.33 Crores divided into 9,06,57,751 equity shares of face value ₹5 each.
| Shareholder Category | Number of Shares Held | % of Total Issued Equity Shares |
|---|---|---|
| Promoter & Promoter Group | 3,90,58,464 | 43.08% |
| Foreign Portfolio Investors (FPIs) | 76,06,884 | 8.39% |
| Insurance Companies (LIC & Others) | 48,04,952 | 5.30% |
| Mutual Funds | 7,27,347 | 0.80% |
| Public / Individuals | 3,21,28,514 | 35.44% |
| Bodies Corporate & Others | 63,31,590 | 6.99% |
| Total Issued Share Capital | 9,06,57,751 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
In terms of Section 129(3) of the Companies Act, 2013, salient features of APL’s subsidiaries and joint venture entity are summarized below.
| Entity Name | Corporate Relationship | Country | % Shareholding | FY 2025-26 Turnover (₹ in Crores) | FY 2025-26 PAT (₹ in Crores) |
|---|---|---|---|---|---|
| Aarti Pharmachem Limited | Wholly-Owned Subsidiary | India | 100.00% | 0.00 | (0.005) |
| Aarti USA Inc. | Wholly-Owned Subsidiary | USA | 100.00% | 26.36 | (2.13) |
| Ganesh Polychem Limited | Joint Venture (Equity Method) | India | 50.00% | 262.33 | 8.00 |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
APL maintains treasury and strategic investments valued at ₹193.85 Crores, including investments in equity instruments (Dilesh Roadlines, Aarti Ventures), debentures, and its 50% joint venture stake in Ganesh Polychem Limited (deemed cost ₹162.07 Crores).
- Credit Ratings: CRISIL Ratings Limited affirmed CRISIL AA-/Stable for long-term bank facilities and issuer ratings.
- Banking Consortium: Credit facilities are consortium-arranged across Axis Bank Limited, Citibank N.A., Kotak Mahindra Bank Limited, Standard Chartered Bank, IDBI Bank Limited, and ICICI Bank Limited.
- Contingent Liabilities: Total contingent liabilities as of March 31, 2026 stood at ₹7.94 Crores, consisting entirely of bank guarantees issued to statutory authorities. Income tax disputes outstanding were reduced to Nil (compared to ₹5.43 Crores in FY 2024-25). Capital commitments for executed projects totaled ₹28.93 Crores.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
APL’s market standing is fortified by core operational and strategic moats:
- Backward Integration & Non-Chinese Sourcing: Fully integrated synthesis routes for Xanthine derivatives and generic APIs shield customers from supply disruptions and geopolitical sourcing risks.
- High Entry Barriers: Commercial supply into regulated markets requires multi-year regulatory documentation, DMF/CEP filings, customer validation, and stringent USFDA audit compliance.
- Multipurpose Flexible Capacity: Over 1,500 KL of fungible reactor volume across API finished lines, supported by specialized flow chemistry, continuous biocatalysis, and cryo-reactors (-100°C to +150°C).
- EcoVadis Gold & SBTi ESG Benchmark: Recognized in the top 5% globally by EcoVadis; first Indian pharmaceutical firm with SBTi-validated emission reduction targets.
What Could Go Wrong? Key Challenges & Business Risks
The Management Discussion and Analysis identifies key operational, market, and regulatory risks:
- Raw Material Price Volatility: Petrochemical input costs (solvents, methanol, ammonia, propylene) fluctuate with West Asian geopolitical tensions.
- Regulatory & Compliance Risk: Heightened USFDA and CDSCO scrutiny requires continuous investments in data integrity, impurity testing, and Quality Management Systems (QMS).
- API Generic Pricing Pressure: Price corrections and customer inventory destocking in select mature generic APIs weigh on short-term margin expansion.
- Foreign Exchange Risk: Unhedged or non-designated foreign currency derivative positions expose quarterly earnings to mark-to-market valuations.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
APL is targeting a 15–18% revenue and EBITDA CAGR over the next 3 to 4 years on a standalone basis, anchored by capital investments moving into active commercial utilization.
- Ramp-Up of Atali Phase 1: Commercial utilization of Block 1 (450+ KL) to drive CDMO and advanced intermediate volume growth throughout FY 2026-27.
- Ground-Breaking of Atali Block 2: Dedicated project block planned for specific CDMO contracts, with ground-breaking scheduled for Q3 FY 2026-27 and targeted completion within 12–15 months.
- Tarapur Xanthine Expansion: Phased commercialization of Tarapur Unit 5 from 5,000 MTPA to 9,000 MTPA, aiming to increase global Xanthine market share from 15–20% to 20–25%.
- TIDES Technology Platform: Strategic R&D investments initiated in peptide and oligonucleotide chemistries to capture emerging biopharmaceutical outsourcing opportunities.
The Verdict: Strategic Outlook & Conclusion
Aarti Pharmalabs Limited has built a high-barrier pharmaceutical manufacturing platform. By pairing backward-integrated Xanthine cash flows with generic API scale and a fast-growing small-molecule CDMO franchise, APL is positioning itself to capture global supply chain diversification opportunities. As recent capital investments transition into full commercial utilization, the Company is prepared to deliver earnings growth and sustainable value creation.
Frequently Asked Questions (FAQs) About Aarti Pharmalabs
Q1: What does Aarti Pharmalabs Limited manufacture, and what are its core business segments?
Aarti Pharmalabs Limited manufactures generic Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, Xanthine derivatives (caffeine, theophylline, aminophylline, etofylline), and provides Contract Development and Manufacturing Organisation (CDMO/CMO) services for small-molecule innovator drugs.
Q2: What were Aarti Pharmalabs’ revenue and net profit figures in FY 2025-26?
In FY 2025-26, Aarti Pharmalabs reported consolidated revenue from operations of ₹1,819.44 Crores, an EBITDA of ₹402.42 Crores (22.12% margin), and a Consolidated Profit After Tax (PAT) of ₹174.71 Crores.
Q3: Who manages Aarti Pharmalabs, and what leadership changes were announced?
The Company is led by Chairman Shri Rashesh C. Gogri, Vice Chairperson & Managing Director Smt. Hetal Gogri Gala, and Managing Director Shri Narendra J. Salvi. Effective October 01, 2026, Shri Rashesh C. Gogri will assume the role of Managing Director, while Smt. Hetal Gogri Gala will transition to Whole-time Director.
Q4: Where are Aarti Pharmalabs’ primary manufacturing plants located, and what is its export footprint?
APL operates 15 units across Maharashtra (Tarapur, Dombivli, Nerul) and Gujarat (Vapi, Atali). International exports accounted for 55.95% of total operational revenues in FY 2025-26, serving customers across more than 50 countries.
Q5: What is Aarti Pharmalabs’ debt profile, credit rating, and net worth?
As of March 31, 2026, APL reported a consolidated net worth of ₹2,124.60 Crores, non-current borrowings of ₹185.81 Crores, current borrowings of ₹499.82 Crores, and a net debt-to-equity ratio of 0.35x (0.32x standalone). The Company maintains a CRISIL AA-/Stable credit rating.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.aartipharmalabs.com